Janet Pope Janetbirdope
2 months ago
#Autoimmune #progressive #pulmonary #fibrosis
Large Spanish registry
❎more mortality if not on #DMARDs
?underRx of proven #Rx with #antifibrotics
Median survival post #dx #PPF 7.8 yrs
Can we do better?
#ABST POS0430
@RheumNow #EULAR2026 https://t.co/gP7apxfEPS
Jiha Lee JihaRheum
2 months ago
Treating inflammation and obesity in PsA with IXEKIZUMAB AND CONCOMITANT TIRZEPATIDE effective with no new safety signals
OP069 @RheumNow #EULAR2026 https://t.co/rkhYvZWpHn
Nelly ZIADE 🍀 Nellziade
2 months ago
💉 Add tirzepatide to biologics in obese #PsA?
#POS0050: Yes! Propensity score-matched study (n=93):
better PROs, HAQ & PASI at 6 months
#EULAR2026 @RheumNow
@vincevenerito https://t.co/rrhNKZByjc
sheila RHEUMarampa
2 months ago
Pts with AIIRD carry a high risk & burden of infection due to immune dysregulation, comorbids, GC/DMaRD use.
As a rheumatologist, do you vaccinate your patients?
#EULAR2026 @RheumNow
sheila RHEUMarampa
2 months ago
#Vaccination in Rheum
📍Hold MTX 1-2wks post vax
📍For Bcell depleters, timing is based on B-cell repop’n kinetics, not fixed calendar intervals.
THM: Assess vax need at dx, vax w/o delay
#EULAR2026 @RheumNow https://t.co/6ptl8gyBLR
Pharmaceutical companies are presenting pivotal clinical trial results and key data analyses at the EULAR 2026 Congress (June 3–6, London). Below is a summary of their most important studies — many of which are registration-enabling or will directly shape treatment decisions in rheumatic diseases.
